Price action
Daily adjusted bars
Snapshot
Key stats
- Market cap
- $32.57B
- P/E ratio
- 12.74
- Forward P/E
- 11.44
- Beta
- 0.86
- 52W range
- $72.38 - $169.60
- Dividend yield
- 2.59%
- Volume
- 1.91M
- Sector
- HEALTHCARE
Analyst
Consensus price target
Current
$77.04
Target
$124.59
AlphaYou verdict
Insider Cluster
2 insiders bought $653K of ZTS this 14d.
- Smart money10.2/40
- Fundamentals0.0/35
- Technicals2.0/15
- Macro1.8/10
Receipts
Recent signals for this ticker
- LONGMay 14Insider Cluster
2 insiders bought $653K of ZTS this 14d.
Public Recommendation·Checkpoints pending - ContextMay 13Insider Buy
Insider bought $233K of ZTS this 14d.
Watch · Mixed Evidence·Checkpoints pending
Smart money
Insider, fund, and political flow
insider buy
Director Bisaro Paul bought $152K
insider buy
Director DAMELIO FRANK A bought $501K
filing 13f fund flow
Renaissance Technologies LLC holds $53.4M (13F 2025-12-31)
filing nport p fund flow
Janus Investment Fund (legacy active) holds $182.2M (NPORT-P 2026-09-30)
filing 13f fund flow
Citadel Advisors LLC holds $37.9M (13F 2025-12-31)
filing 13f fund flow
Two Sigma Investments LP holds $13.9M (13F 2025-12-31)
Top trader activity
PendingCopy-trading signal layer from real US-equity operators. Wires in once the CopyTrading feed is mapped to US-stock tickers.
BTC Astro risk regime
PendingCross-asset risk timing overlay. Used as context only, never a primary stock source.
Reputation
Sources and actors behind this ticker
Source families
- SEC EDGAR Form 4
Source family
D7
92
+2.22%
66.3% hit
D15
28
+1.41%
60.7% hit
D30
pending
Actors and filers
- Bisaro Paul
INSIDER
D7
1
+6.53%
100.0% hit
D15
pending
D30
pending
- DAMELIO FRANK A
INSIDER
D7
1
+6.53%
100.0% hit
D15
pending
D30
pending
Checkpoint ledger
Public recommendation outcomes
No public recommendation checkpoints have landed for this ticker yet.
D7 appears first, then D15 and D30 as the call matures.
Each row is a public recommendation. Alpha columns compare the frozen issued price with SPY, QQQ, and sector ETF checkpoints when available.
Raw source coverage
Primary-source receipt chain
Fundamentals
Valuation, quality, growth
Valuation
- P/E12.74
- Forward P/E11.44
- P/S3.42
- P/B10.15
Quality
- Profit margin28.0%
- Operating margin36.6%
- ROE67.7%
- ROA15.5%
Growth
- Revenue YoY--
- Earnings YoY--
- Beta0.86
- Dividend yield2.6%
Technicals
Trend, momentum, levels
Trailing returns
- 5d+0.22%
- 20d-1.37%
- 60d+1.50%
Trend vs SMAs
- vs SMA50+0.30%
- vs SMA200+1.51%
52w range position
Computed from AV daily adjusted bars. No options-flow, IV, or order-book signals on this page yet.
Macro
Sector + regime context
- +18.0
macro regime shift
VIX 18.0 (mild) as of 2026-05-12
- +0.5
macro regime shift
10y-2y spread 46bps (flattish) as of 2026-05-12
- +101.8
macro regime shift
Industrial Production 101.8 (flat) as of 2026-03-01
- +0.9
macro regime shift
Initial claims 200,000 vs 26w mean (ratio 0.93, subdued)
- +4.0
macro regime shift
CPI YoY 3.95% (hot vs Fed target)
Earnings
EPS beat / miss history
No stored earnings history for this ticker.
The AV EARNINGS sweep backfills 8+ quarters per coverage cycle.
Debate
Key issues
Bullish view
- Director Bisaro Paul bought $152K
- Director DAMELIO FRANK A bought $501K
- Renaissance Technologies LLC holds $53.4M (13F 2025-12-31)
- Janus Investment Fund (legacy active) holds $182.2M (NPORT-P 2026-09-30)
Bearish view
No receipts on this side yet.
Arguments are pulled from contributing receipts (Form 4 / 13F / fundamentals / macro) for this ticker. Each side carries the count of receipts behind it, not an analyst headline count.
Track record
Recommendation receipts
vs SPY
S&P 500
Median alpha
+6.53%
Mean alpha
+2.27%
Hit rate
66.7%
Mean return
+1.87%
vs QQQ
Nasdaq-100
Median alpha
+6.33%
Mean alpha
+2.26%
Hit rate
66.7%
Mean return
+1.87%
D7 recommendation-counted alpha. Each receipt aggregates same-day same-direction signals into one row to avoid double-counting.